TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022
|Conference call and webcast:|
|Dial-in:||(855) 779-9066 (Domestic) or (631) 485-4859 (International)|
|Via web:||www.traconpharma.com; “Events and Presentations” section within the “Investors” section|
A replay of the webcast will be available for 60 days on the website.
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads
|Company Contact:||Investor Contact:|
|Chief Business Officer|
|(858) 251-3492||(212) 915-2578|
Source: TRACON Pharmaceuticals, Inc.